Phase II Dual-Cohort Study Evaluating the Effects of Pembrolizumab in the Presence of Gut Microbiota Modulation With EDP1503 in Advanced Melanoma Naive or Refractory to Anti-PD1 Antibody
Phase of Trial: Phase II
Latest Information Update: 28 Jan 2019
At a glance
- Drugs EDP-1503 (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 28 Jan 2019 According to an Evelo Biosciences media release, first patient has been dosed in this trial.
- 12 Nov 2018 Status changed from not yet recruiting to recruiting.
- 30 Jul 2018 New trial record